Version May 2024
| Absolute contraindications |
| Systemic illness with a life expectancy <2 years despite heart transplantation |
| Irreversible pulmonary hypertension with pulmonary vascular resistance >3 Wood Units (>240 dynes-sec/cm5)[1]* |
| Clinically severe symptomatic cerebrovascular disease |
| Active substance (drug or alcohol) abuse |
| Multiple demonstrations of inability to comply with drug therapy |
| Multisystem disease with severe extracardiac organ dysfunction |
| Relative contraindications |
| Age >70 years¶ |
| Obesity (ie, body mass index >35 kg/m2) |
| Diabetes mellitus with poor glycemic control (glycated hemoglobin [HbA1c] >7.5% or 58 mmol/mol) despite optimal effort or end-organ damage other than non-proliferative retinopathy |
| Irreversible renal dysfunction (eGFR <30 mL/min/1.73 m2)Δ |
| Neoplasm (requires individualized assessment of severity, treatment options, and prognosis) |
| Infection (requires individualized assessment of severity, treatment options, and prognosis) |
| Acute pulmonary embolism (within six to eight weeks) |
| Tobacco use (within 6 months) |
| Recent past (within 6 months) substance (drug or alcohol) abuse |
| Inadequate social support or cognitive-behavioral disability that would prevent compliant care |
| Other conditions that increase the risk of perioperative complications or limit tolerance of immunosuppression (eg, peripheral vascular disease that would limit rehabilitation and is not amenable to revascularization, active peptic ulcer disease, cholelithiasis, diverticulosis, advanced hepatic disease) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
